Diabetic neuropathy is a type of nerve damage that can occur in individuals with diabetes, particularly those who have had the condition for a long time. The treatment of diabetic neuropathy aims to manage symptoms and prevent further nerve damage.
Latest Diabetic Neuropathy Treatment Companies Update
Oct 2023: After receiving final approval for Apremilast Tablets (10 mg, 20 mg, and 30 mg variants) from the U.S. FDA, Glenmark Pharmaceuticals Ltd.'s shares increased by 1.24 percent. These pills function as a generic substitute for Otezla pills made by Amgen Inc. Notably, according to IQVIATM data for the 12 months ending in August 2023, Otezla Tablets achieved roughly $3.7 billion in annual sales. With 50 ANDAs awaiting approval and a lineup of 188 items now approved for sale in the US market, Glenmark is steadfast in pursuing outside alliances to expand its current offering.
Nov 2023: In nations recognizing the CE mark, Roche has released the Elecsys®Anti-HEV IgM and Elecsys Anti-HEV IgG immunoassays to identify hepatitis E virus (HEV) infections. Clinicians can help their patients find the source of their symptoms, choose the best treatment, keep an eye out for the development of severe acute HEV, and stop the progression of severe disease by using antiviral therapy by testing for HEV infection. To enhance timely and life-saving diagnoses, the World Health Organization (WHO) has produced an "Essential Diagnostics List" that includes in-vitro diagnostics that should be accessible in all nations. To help with the diagnosis and surveillance of HEV infection, HEV tests are now included this year for the first time.
Diabetic Neuropathy Treatment Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)